Princeton, June 2004 © Risk Management Resources 1 The Risk Management Initiatives and Drug Development Felix M Arellano, MD, Dip Pharm Med, FISPE.

Slides:



Advertisements
Similar presentations
Mary Ellen Turner MD, MPH Vice-President
Advertisements

Regulatory Clinical Trials Clinical Trials. Clinical Trials Definition: research studies to find ways to improve health Definition: research studies to.
RMP: DEFINITIONS AND REGULATORY ASPECTS Marc Czarka, MD, FBCPM Managing Partner HM3A ( Market Autorisation and Access Associates )
06/05/2015 Risk Management Plan 24. April 2008 Helge Gydesen Epidemiology Novo Nordisk A/S.
Integrating CMC Review & Inspection Industry Recommendations Joe Anisko April 24, 2003.
Kori Talbott, PharmD PGY1 Pharmacy Resident Eastern States May 2013 Incorporation of REMS (Risk Evaluation and Mitigation Strategies) into daily clinical.
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development Critical Path.
Special Topics in IND Regulation
Objectives Why we need DHCPL Situations that call for a DHCPL Definitions DHCPL itself–content, presentation, process Target audience Current and future.
Postmarketing Risk Assessment of Drug Products Division of Drug Risk Evaluation Office of Drug Safety Center for Drug Evaluation and Research.
1 Alvimopan RiskMAP Joyce Weaver, Pharm.D., BCPS Office of Surveillance and Epidemiology.
1 Revisions to 21 CFR Supplements and Other Changes to an Approved Application PhRMA Perspective FDA Public Meeting – 7 Feb 2007.
GLOBAL REGULATORY STRATEGY CONSIDERATIONS SCIENTIFIC SARAH POWELL EXECUTIVE DIRECTOR, REGULATORY STRATEGIES SEPTEMBER 14-17, 2008 BOSTON, MA.
FDA Recalls Risk Communication Advisory Committee David K. Elder Director, Office of Enforcement.
Stages of drug development
IPhVWP Polish Presidency, Warsaw October 6 th 2011 Almath Spooner Irish Medicines Board Monitoring the outcome of risk minimisation activities.
July 2015 PRABHAVATHI FERNANDES, PhD Founder, President and CEO How the PATH Act Can Rejuvenate Antibiotic R & D.
Achieving and Demonstrating “Quality-by-Design” with Respect to Drug Release/dissolution Performance for Conventional or Immediate Release Solid Oral Dosage.
Eureka Pre-Clinical Investigation Animal toxicology Animal pharmacokinetics/ pharmacodynamics Clinical Investigation Phase I Safety and pharmacology Phase.
Geriatric Medicines Strategy - Informal PhVWP Oct EMA Geriatric Medicines Strategy: focus on Pharmacovigilance Francesca Cerreta EMA, H-SE-CNS.
Center for Veterinary Medicine (CVM) RECALLS.  21 CFR 7.40 provides guidance on the policy, procedures, and industry responsibilities for recalls. 
Justina A. Molzon, MS Pharm, JD
Industry Perspective on Challenges for Product Developers - Drugs Christine Allison, M.S., RAC Associate Regulatory Consultant, Global Regulatory Affairs.
Investigational New Drug Application (IND)
Changes without Prior Approval Breakout Session Summary Rick Smith Aventis Pasteur, Inc.
ICH V1 An FDA Update Min Chen, M.S., RPh Office of Drug Safety Center for Drug Evaluation and Research FDA January 21, 2003.
Development and application of guidance documents – industry view Dr Martin Schaefer ECCA-ECPA Conference March 2014.
Understanding the Pre-IDE Program: FDA Perspective
Reproductive Health Drugs, Pregnancy Labeling Subcommittee Meeting March 28-29, 2000 Holli A. Hamilton, M.D., M.P.H. Pregnancy Labeling Team Office of.
Drug Submissions: Review Process Agnes V. Klein, MD Biologics and Genetic Therapies Directorate February, 2003 www/hc-sc.gc.ca/hpb-dgps/therapeut.
Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.
© Safeguarding public health Building a sustainable framework for medical devices regulation Graeme Tunbridge Medicines and Healthcare products Regulatory.
Risk Management Strategy for the Pharma and Biotech Product Lifecycle : New Regulatory and Legal Focus and Approach Morgan, Lewis & Bockius, LLP August.
Proposal for End-of-Phase 2A (EOP2A) Meetings Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee November 17-18, 2003 Lawrence.
Sidney M. Wolfe M.D and Sherri Shubin M.D., M.P.H. Public Citizen’s Health Research Group FDA Drug Safety and Risk Management and Dermatologic and Ophthalmic.
Developing medicines for the future and why it is challenging Angela Milne.
PhRMA Perspective on FDA Final Report FDA Advisory Committee on Pharmaceutical Sciences October 20, 2004 G.P. Migliaccio, Pfizer Inc.
FDA Risk Management Workshop – Day #3 April 11, 2003 Robert C. Nelson, Ph.D. RCN Associates, Inc Annapolis, MD, USA.
FDA Regulatory and Compliance Symposium
1 Operation of the Prescription Drug User Fee Program Janet Woodcock, M.D. Deputy Commissioner for Operations November 14, 2005.
Cardiovascular Health Research Unit, Seattle, WA IOM recommendations on drug safety: relevance for vaccines? Bruce M Psaty, MD, PhD.
1 Public Workshop on Risk Management Day 2 – Risk Management Programs Washington DC, April 10 International Society for Pharmacoepidemiology S. Pérez-Gutthann,
General Regulatory Issues in the Development of Drugs Intended for Treatment of Chronic Illness Sharon Hertz, M.D. Medical Officer Division of Anesthetic,
July 15, Postmarketing Safety Evaluation of Approved Drugs and Risk Management Victor F. C. Raczkowski, MD, MS Director, Office of Drug Safety July.
FDA job description  Regulates about 25% of all consumer purchases  Mission summary: protect and advance public health  Products: food, cosmetics, drugs,
1 Drug Safety Oversight Board: Recent Activities FDA Science Board Advisory Committee Meeting March 31 st, 2006 Douglas C. Throckmorton, MD Deputy Director.
October 28, F OOD AND DRUG ADMINISTRATION AMENDMENTS ACT OF 2007 (FDAAA) and Risk Evaluation and Mitigation Strategies (REMS) Presented to the Ninth.
Comparability Protocols Nancy Sager Associate Director, QIS-Chemistry FDA/CDER/OPS.
Applying New Science to Drug Safety Janet Woodcock, M.D. Acting Deputy Commissioner for Operations April 15, 2005.
1 PRIORITY MEDICINES FOR EUROPE AND THE WORLD Barriers to Pharmaceutical Innovation Richard Laing EDM/PAR WHO.
12/4/031 Drug Safety and Risk Management Advisory Committee Advancing the Science of Proprietary Drug Name Review Paul J. Seligman, MD.
Postmarketing Pharmacovigilance English D. Willis, MD Clinical Risk Management Merck Research Laboratories June 1, 2012.
27 June 2000Victor F. C. Raczkowski, M.D.1 Risk-Management Options Victor F. C. Raczkowski, M.D., M.S. Gastrointestinal Drugs Advisory Committee 27 June.
© Copyright IBM 2007DIA ERS SIAC Presentation, January 2008 The HL7 RPS and SPL Standards - A High Level View Terry Hardin Sr. IT Architect Emerging Software.
GCP (GOOD CLINICAL PRACTISE)
FDA DRUG APPROVAL FDA’s Lengthy Drug Approval Process in Twelve Steps Overview of the FDA Drug Approval Process Drug Developed June 13, 2016 | Emilia Varrone.
November 9, 2015 February 20, 2017 Using real world evidence – industry perspective Pma indication expansion Melissa hasenbank, phd Sr. Clinical Research.
Principles of Risk Management
Use of Postmarket Data to Support Premarket Approvals
Pre-Investigational New Drug (pre-IND) Meeting with FDA
ICH-GCP Avinash Kondawar M. Pharm Lead CRA
Balancing Pre and Postmarket Requirements Different Scenarios
Reasonable Assurance of Safety and Effectiveness: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division.
First-in-Man, First In The USA: What’s The Difference?
Formal Meetings between FDA and Sponsors of PDUFA Products
Medical Device Regulatory Essentials: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
Combination products The paradigm shift
Speeding access to therapies
The International Drug Safety Paradigm
Suzanne M. Sensabaugh, MS, MBA
Presentation transcript:

Princeton, June 2004 © Risk Management Resources 1 The Risk Management Initiatives and Drug Development Felix M Arellano, MD, Dip Pharm Med, FISPE

2Princeton, June 2004© Risk Management Resources Definitions. Pharmacovigilance Plan (PVP) All products launched with PVP Data from pre-clinical development Data from pre-clinical development Data from clinical development Data from clinical development Class or “family” safety “issues” Class or “family” safety “issues” Data from population intended to receive the agent Data from population intended to receive the agent Steps needed to gain further knowledge Steps needed to gain further knowledge PVP (ICH) = PV Specification + Action Plan

3Princeton, June 2004© Risk Management Resources Risk Minimization Action Plan (formerly Risk Management Plan) RMP. Similar to PVP + Risk assessment/measurement Risk assessment/measurement Risk confrontation Risk confrontation Risk intervention (minimization or tools) Risk intervention (minimization or tools) Risk management evaluation Risk management evaluation Risk communication Risk communication RM (FDA) = Risk assessment + risk minimization

4Princeton, June 2004© Risk Management Resources Risk Management

5Princeton, June 2004© Risk Management Resources Where we are FDA PDUFA III. Pre NDA meeting packages should include safety information and proposal for Risk Management Plans (RMP) Pre NDA meeting packages should include safety information and proposal for Risk Management Plans (RMP) NDA Review. RMP must be submitted no later than one month prior to official action date NDA Review. RMP must be submitted no later than one month prior to official action date Guidance Papers. 2 nd draft released on May 5 th and is open for comments Guidance Papers. 2 nd draft released on May 5 th and is open for comments Implementation expected in 2004

6Princeton, June 2004© Risk Management Resources Where we are (cont.) EMEA. EU Heads of Agencies developed a “EU Risk Management Strategy” in January 2003 Guidance on Risk Management can be obtained during “scientific advice” Guidance on Risk Management can be obtained during “scientific advice” By the time of approval all products are expected to have a RMP or a statement that no specific “safety measure” is needed By the time of approval all products are expected to have a RMP or a statement that no specific “safety measure” is needed

7Princeton, June 2004© Risk Management Resources Where we are (cont.) ICH Guideline (E2E) has been adopted by FDA FDA will issue its guidelines in 2004

8Princeton, June 2004© Risk Management Resources Where we are (cont.) RM concept has shifted RMP were originally designed to manage KNOWN risks (terfenadine, mebefranil, astemizole, bromfenac)

9Princeton, June 2004© Risk Management Resources Where we are (cont.) RM concept now involves pre-marketing risk assessment during which, by definition, post-marketing risks are not known

10Princeton, June 2004© Risk Management Resources Why is RM here? Perception vs. Reality General perception of an “increased regulatory pressure”: There are less regulatory approvals There are less regulatory approvals More drugs are withdrawn More drugs are withdrawn Agencies are more cautious in granting approvals Agencies are more cautious in granting approvals

11Princeton, June 2004© Risk Management Resources Average Number of Drugs Approved per Year. FDA DecadeNo. Drugs 1940s3 1950s s s s s41

12Princeton, June 2004© Risk Management Resources Last 5 years of the 20 th Century (FDA) Almost a drug per week!!!

13Princeton, June 2004© Risk Management Resources Number of NME/NDA Approved per Calendar Year NDA Standard NME Expedited NME

14Princeton, June 2004© Risk Management Resources Number of NMEs Withdrawn as a Percentage of NME Approved Number Proportion

15Princeton, June 2004© Risk Management Resources Proportion of Standard NDA Approved

16Princeton, June 2004© Risk Management Resources Proportion of Standard NDA Approved

17Princeton, June 2004© Risk Management Resources Number of Drug Safety Alerts ( ) clinical alert of SAEs, black box warnings, voluntary recalls, counterfeits and market withdrawals CAGR 18%

18Princeton, June 2004© Risk Management Resources Number of Safety – Related Label Changes ( ) CAGR 21% Flat after 1997 – 1998 Skepticism over effectiveness of label changes as RM tool

19Princeton, June 2004© Risk Management Resources Why is RM here? Perception vs. Reality General Perception of an increased regulatory pressure: There are less regulatory approvals +/- There are less regulatory approvals +/- More drugs are withdrawn + More drugs are withdrawn + Agencies are more cautious in granting approvals + Agencies are more cautious in granting approvals + Overall increase in regulatory pressure over label changes ++ Overall increase in regulatory pressure over label changes ++

20Princeton, June 2004© Risk Management Resources Why do companies need RM? It is the right thing to do It is here, whether you like it or not R & D reasons: R & D reasons: Leaner Pipelines Leaner Pipelines Less “unmet medical needs” Less “unmet medical needs” Narrower indications Narrower indications Higher R & D Costs Higher R & D Costs

21Princeton, June 2004© Risk Management Resources Why do companies need RM? (cont) Regulatory Reasons Agencies (and society) are becoming increasingly risk-averse Agencies (and society) are becoming increasingly risk-averse Smaller benefits; make benefit: risk analysis challenging Smaller benefits; make benefit: risk analysis challenging “Err on caution” translates in restrictions, delays, withdrawals (or all the above) = lower revenues “Err on caution” translates in restrictions, delays, withdrawals (or all the above) = lower revenues Opportunity is to translate challenge to advantage

22Princeton, June 2004© Risk Management Resources What to Expect Compliance must be a given Focus on life cycle management Peri-launch and post-marketing periods are simply part of a continuum Peri-launch and post-marketing periods are simply part of a continuum Sponsors cannot be expected to predict completely the safety profile… But they will be expected to follow up on the identified ones, and… But they will be expected to follow up on the identified ones, and… Actively look for new ones Actively look for new ones

23Princeton, June 2004© Risk Management Resources PVP/RMP in Development Pharmacovigilance Plans (PVP) starting in exploratory development and being followed through development

24Princeton, June 2004© Risk Management Resources Risk Communication Of all the components of the RMP this is the most complex, multidisciplinary and challenging Balance between adequate, and exaggerated Communication of risk falls on underlying perceptions of the receiver

25Princeton, June 2004© Risk Management Resources

26Princeton, June 2004© Risk Management Resources Risk Communication

27Princeton, June 2004© Risk Management Resources Issues Monumental task impossible to tackle pleasing everyone Categorization of drugs was removed from new version Risk minimization, not avoidance. Risk reduction better Endorses RM as part of life-cycle Endorsees and guides on RM in pre and post-marketing

28Princeton, June 2004© Risk Management Resources Issues. Cons Lack of precision regarding when to prepare PVP and RMAP as well as “routine PV” Confusion around whether RM will narrow exposure to drugs Older drug issue not tackled Avoiding need for PVP Contradiction with ICH E2E (endorsed by FDA) Label as risk communication tool and cornerstone Exclusion of industry from certain forums

29Princeton, June 2004© Risk Management Resources Issues Will companies take RM seriously without clear guidelines? Precedents are not reassuring Precedents are not reassuring Traditionally, pharmacovigilance is considered an expense, not an investment

30Princeton, June 2004© Risk Management Resources Issues Distribution of burden among society members Including patients, and its “informed” consent

31Princeton, June 2004© Risk Management Resources Issues (cont) Implementation of RM concept cannot be harmonized Information overload Not a panacea. E.g. toxicity in elderly due to misadministration

32Princeton, June 2004© Risk Management Resources THANK YOU

33Princeton, June 2004© Risk Management Resources 4 Oak Lane Califon, NJ 07830, USA